Cover Image
市場調查報告書

EpiCast Report:腎細胞癌的流行病學預測

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023

出版商 GlobalData 商品編碼 311413
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:腎細胞癌的流行病學預測 EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023
出版日期: 2016年06月01日 內容資訊: 英文 43 Pages
簡介

腎細胞癌(RCC),是產生在近曲小管內膜的腎臟癌的一種。全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、日本、中國)的腎細胞癌的發病數量,預計從2013年的186,179件,今後10年增加6.25%到302,449件。

本報告提供全球主要8個國家的腎細胞癌調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 發病率
    • 存活率 - 主要8個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法,接受診斷的發病數量
    • 預測的前提條件與手法,接受診斷的5年患病數量
    • 預測的前提條件與手法,診斷的時候臨床階段
  • 腎細胞癌的流行病學預測
    • 受到了診斷的發病數量
    • 受到了診斷的發病數量:各年齡
    • 受到了診斷的發病數量:性別
    • 受到了診斷的發病率:年齡標準化
    • 受到了診斷的腎細胞癌數:診斷時的各臨床階段
    • 受到了診斷的5年患病數量
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER119-16

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, being responsible for approximately 90% of all cases in adults. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine, flank pain, a mass in the abdomen or flank, weight loss, fever, hypertension, night sweats, and a general feeling of being unwell. Kidney cancer is among the 10 most frequently occurring cancers in Western countries. Globally, about 270,000 cases of kidney cancer are diagnosed yearly, and 116,000 people die from the disease.

GlobalData epidemiologists forecast an increase in the diagnosed incident cases of RCC in the 8MM, from 190,147 diagnosed incident cases in 2013 to 309,734 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 6.29% during the forecast period. In 2023, urban China will have the highest number of diagnosed incident cases of RCC in the 8MM, with 147,457 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of RCC, with 7,591 diagnosed incident cases. Similarly, as shown in the second figure below, the five-year diagnosed prevalent cases of RCC in the 8MM will increase from 600,261 diagnosed prevalent cases in 2013 to 966,190 diagnosed prevalent cases in 2023, with an AGR of 6.10% during the forecast period. The increase in the diagnosed five-year prevalent cases of RCC is partly attributed to the rising trend in the incidence rate of RCC in the 8MM, combined with changes in the population demographics in the respective markets.The rising trend in the incidence of RCC may partly be a result of increased use of imaging techniques that can detect asymptomatic tumors.

Scope

  • The Renal cell carcinoma (RCC) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for RCC in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). It includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC, segmented by age (at 20-year intervals, starting at age 20 years and ending at ages =80 years) and sex. It also includes a forecast of the five-year diagnosed prevalent cases of RCC in the 8MM. Additionally, it provides the RCC diagnosed incident cases, segmented by the stage at diagnosis, for the 8MM.
  • The RCC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The RCC EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global RCC market.
  • Quantify patient populations in the global RCC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RCC therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. Incidence
    • 3.3.2. Survival Rates for RCC - 8MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, RCC Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, RCC Five-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, RCC Clinical Stages at Diagnosis
  • 3.5. Epidemiological Forecast for RCC (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of RCC
    • 3.5.2. Age-Specific Diagnosed Incident Cases of RCC
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of RCC
    • 3.5.4. Age-Standardized Diagnosed Incidence of RCC
    • 3.5.5. Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis
    • 3.5.6. Five-Year Diagnosed Prevalent Cases of RCC
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: RCC Clinical Stages at Diagnosis
  • Table 2: Risk Factors and Comorbidities for RCC
  • Table 3: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007
  • Table 4: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007
  • Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007
  • Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007
  • Table 7: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2009
  • Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases
  • Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases
  • Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis
  • Table 11: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013
  • Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023
Back to Top